20-Fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw

Lancet

Volumn 357, Issue 9260, 2001, Pages 934-935

  Zöllner, Bernhard ^a   Petersen, Jörg ^a   Schröter, Matthias ^a   Laufs, Rainer ^a   Schoder, Volker ^a   Feucht, Heinz Hubert ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; MEMBRANE ANTIGEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME;

EID: 0035942013     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04219-7     Document Type: Article

References (5)

1. A one-year trial of lamivudine for chronic hepatitis B
2. Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains
3. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
4. In vivo dynamics and pathogenicity of wild-type and resistant hepatitis B virus during long-term lamivudine monotherapy - A clinical note
5. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA